X4 Pharmaceuticals Changes Fiscal Year End
Ticker: XFOR · Form: 8-K · Filed: Apr 24, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, fiscal-year-change
TL;DR
X4 Pharma is changing its fiscal year end to Dec 31st.
AI Summary
On April 24, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end to December 31st. Previously, the company was known as Arsanis, Inc. and changed its name on September 20, 2010.
Why It Matters
This filing signals a potential shift in X4 Pharmaceuticals' reporting structure and financial calendar, which could impact how investors and analysts track its performance.
Risk Assessment
Risk Level: low — The filing is a routine administrative update regarding the company's fiscal year end and does not involve significant financial or operational changes.
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former company name
- April 24, 2025 (date) — Date of report
- December 31 (date) — New fiscal year end
- September 20, 2010 (date) — Date of former name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in the registrant's fiscal year end.
When is the new fiscal year end for X4 Pharmaceuticals, Inc.?
The new fiscal year end for X4 Pharmaceuticals, Inc. is December 31.
What was X4 Pharmaceuticals, Inc. formerly known as?
X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc.
When did the company change its name from Arsanis, Inc.?
The company changed its name from Arsanis, Inc. on September 20, 2010.
What is the principal executive office address for X4 Pharmaceuticals, Inc.?
The principal executive office address for X4 Pharmaceuticals, Inc. is 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2025 regarding X4 Pharmaceuticals, Inc (XFOR).